Latest Research on Lactobacillus Gasseri Probiotics for Weight Loss

A microbial combination for weight loss comprising Lactobacillus gasseri and Akkermansia muciniphila, with a specific ratio of 40-60 copies of each bacterium. The combination is prepared by culturing the bacteria in separate media and then combining them in a pharmaceutical composition for oral administration. The composition is used to treat obesity and related metabolic disorders, such as hypertension, hyperlipidemia, and diabetes.

Source

Lactobacillus acidophilus strain GOLDGUT-LA100 with bile salt hydrolase activity for lowering cholesterol, blood glucose, and body weight. The strain is isolated from human intestines, identified by 16S rDNA sequencing, and characterized by high bile salt hydrolase activity and gastric acid tolerance. It reduces serum cholesterol, body weight, and liver fat in animal models, and modulates macrophage infiltration in adipose tissue. The strain is suitable for development of probiotic products for lipid lowering, blood glucose control, and weight management.

Source

Probiotics with modified energy metabolism that regulate lipid absorption in the gut, comprising bacteria engineered through stress-based directed evolution to either metabolize or store lipids before absorption, thereby reducing body weight in subjects with obesity or overweight conditions.

Source

A diet-reducing capsule containing multi-nutrient microspheres that simultaneously supports weight loss, nutritional supplementation, intestinal health, and probiotic colonization. The capsule combines hydrogel particles with probiotic-prebiotic-vitamin-mineral microspheres, which adhere to the hydrogel surface or are sandwiched between the particles. This microsphere matrix provides a stable environment for probiotic survival and absorption, while the hydrogel maintains its structure. The capsule is freeze-dried to preserve the microspheres' functionality, allowing them to release their active components over time. The combination of probiotics, vitamins, and minerals in the capsule provides a comprehensive nutritional support system for weight management, while the probiotics enhance gut health and satiety.

Source

Methods and compositions for treating weight-related disorders by altering the gut microbiota. The methods involve administering microbiota from specific bacterial phyla, orders, or genera to increase their relative abundance in the gut, thereby promoting weight loss and improving metabolic health. The compositions can include live bacterial strains or compounds that selectively increase or decrease specific microbiota populations. The methods can be used as a standalone treatment or in combination with other therapies, including surgery, to manage obesity and related metabolic disorders.

Source

Compositions comprising a probiotic combination of two or more bacterial strains from different species, including Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus reuteri, Lactobacillus gasseri, Lactobacillus rhamnosus, and Bifidobacterium lactis, for preventing and treating metabolic syndrome and related disorders. The combination is particularly effective when comprising Lactobacillus gasseri and Bifidobacterium lactis, and has been shown to reduce cholesterol, triglycerides, and waist circumference, while also lowering inflammatory markers.

Source

A system for designing personalized microbiome therapeutics and diet based on functions of an individual's microbiome. The system analyzes gut microbiome composition and function to identify dysbiotic states and perturbed metabolic pathways. It generates personalized therapeutic recommendations, including probiotics, prebiotics, and dietary interventions, based on the individual's microbiome profile and functional deficits.

Source

A novel lactic acid bacterium, Lactiplantibacillus Plantarum SKO-001, is disclosed for reducing body fat and preventing obesity. The bacterium exhibits unique properties that enable it to effectively lower body fat levels and improve metabolic health. The invention encompasses various compositions, including food, pharmaceutical, and feed products, containing the SKO-001 strain, its culture, lysate, or extract. These compositions can be used to prevent or treat obesity, metabolic diseases, and related conditions such as diabetes and cardiovascular disease.

Source

ABSTRACT Obesity and overweight among companion animals are significant concerns, paralleling the issues observed in human populations. Recent research has highlighted the potential benefits of various probiotics in addressing weight-related changes, obesity, and associated pathologies. In this study, we delved into the beneficial probiotic mechanisms in high-fat-induced obese canines, revealing that Enterococcus faecium IDCC 2102 (IDCC 2102) and Bifidobacterium lactis IDCC 4301 (IDCC 4301) have the capacity to mitigate the increase in body weight and lipid accumulation in obese canines subjected to a high-fat diet and hyperlipidemic Caenorhabditis elegans ( C. elegans ) strain VS29. Both IDCC 2102 and IDCC 4301 demonstrated the ability to reduce systemic inflammation and hormonal disruptions induced by obesity. Notably, these probiotics induced modifications in the microbiota by promoting lactic acid bacteria, including Lactobacillaceae , Ruminococcaceae , and S24-7 , with concomitant activation of pyruvate metabolism. IDCC 4301, through the generation of bacterial short-chain fatty... Read More

Source

In recent years, interest in probiotics, particularly Lactobacillus strains like Lactobacillus sp. SKG34, isolated from Sumbawa mare milk, has surged due to their potential health benefits. This strain holds promise as a probiotic agent, but understanding its behavior in the gastrointestinal (GI) tract is essential for effective application. This study aimed to investigate the resistance and persistence of Lactobacillus sp. SKG34 in the GI tract of rats. Rats were orally administered the strain at a concentration of 10^8 cells for 30 days. The probiotics ability to modulate gut microbiota and improve host health is a key area of interest. By utilizing techniques like PCR-RAPD, this research sought to elucidate the fate of Lactobacillus sp. SKG34 in the complex environment of the rat GI tract. Results revealed a significant increase in LAB population in cecal contents, from 3.06 x 10^9 cfu/g in the control group to 1.25 x 10^10 cfu/g in the probiotic group. RAPD analysis also detected Lactobacillus sp. SKG34 in approximately 23% of the total population of lactic acid bacteria in ceca... Read More

Source

Abstract Human milk contains a variety of microorganisms that exert benefit for human health. In the current study, we isolated a novel Lactobacillus gasseri strain named Lactobacillus gasseri ( L. gasseri ) SHMB 0001 from human milk and aimed to evaluate the probiotic characteristics and protective effects on murine colitis of the strain. The results showed that L. gasseri SHMB 0001 possessed promising potential probiotic characteristics, including good tolerance against artificial gastric and intestinal fluids, adhesion to Caco2 cells, susceptibility to antibiotic, no hemolytic activity, and without signs of toxicity or infection in mice. Administration of L. gasseri SHMB 0001 (1 10 8 CFU per gram of mouse weight per day) reduced weight loss, the disease activity index, and colon shortening in mice during murine colitis conditions. Histopathological analysis revealed that L. gasseri SHMB 0001 treatment attenuated epithelial damage and inflammatory infiltration in the colon. L. gasseri SHMB 0001 treatment increased the expression of colonic occludin and claudin1 while decreasing... Read More

Source

Abstract Background The prevalence of excess weight and obesity is increasing in an extremely concerning manner worldwide, with highly diverse therapies for current treatment. This review evaluated the scientific evidence of the past 10 years on the use of probiotics in treating excess weight and obesity in the absence of dieting. Materials A systematic review was conducted by searching for clinical trials on humans published in English in the PubMed, Scopus and Cochrane Central databases, using the combination of keywords Overweight, Probiotics and Obesity, and published between 2012 and 2022. Results Six published studies met the inclusion criteria. The review showed that, although there is a lack of consensus in the literature, the use of probiotics in the absence of dieting produced a significant reduction in body weight and body mass index in 66.6% of the reviewed studies, a significant reduction in waist circumference in 80.0% of the reviewed studies, and an improvement in total body fat mass and waist circumference. Conclusions This review showed evidence of a trend in p... Read More

Source

Gut microbiota influences energy homeostasis in part through circulating hormones. Insulin-like growth factor-binding protein (IGFBP)-2 is a biomarker whose increase in systemic circulation is associated with positive effects on body weight and metabolism. In a recent clinical trial, probiotic Lacticaseibacillus rhamnosus HA-114 supplementation showed positive effects on eating behaviors and insulin resistance in overweight participants undergoing a weight-loss intervention. In this context, this ancillary study aimed at assessing the impact of L. rhamnosus HA-114 supplementation on plasma IGFBP-2 levels in these individuals, and whether this modulation correlated with changes in fat mass, energy metabolism, and eating behaviors. Fasting plasma IGFBP-2 concentrations were quantified in 100 overweight or obese men and women enrolled in a 12-week diet-based weight reduction program (500 kcal/day), in combination with probiotic L. rhamnosus HA-114 or placebo supplementation. Baseline and changes in circulating IGFBP-2 concentrations were correlated with anthropometric parameter, glucos... Read More

Source

Introduction: the gut microbiota is a potential determining factor in the development of obesity, resulting in dysbiosis, which is related to a lower number of members of the Bacteroidetes division and an increase in Firmicutes leading to a decrease in energy expenditure, it is also associated with the inflammatory process, insulin resistance and type 2 diabetes mellitus. Objective: to carry out a literature review related to the effects of probiotics on the improvement of the intestinal microbiota in an obese patient and its associated disorders.Methods: a search of articles in PubMed, Google Scholar and Elsevier from the last five years was carried out using the terms "obesity and probiotics", "effect of probiotics", "gut microbiota and probiotics". A total of 23 articles were included in the selection criteria. Results: supplementation with probiotics specifically certain strains such as Lactobacillus plantarum and Bifidobacterium could lead to significant weight reductions, in combination with energy restriction and physical activity. However, it is important to develop clinical ... Read More

Source

Probiotics have multiple beneficial effects on human health, including modulation of the immune system, inhibition of enteric pathogens, and prevention of metabolic disorders. Lactic acid bacteria (LAB) are the most common bacterial strains used for probiotic production. Among those, species belonging to the Lactobacillus acidophilus complex, especially L. gasseri, were well characterized and reported for probiotics. This study evaluated the potential probiotic characteristics of two L. gasseri strains (designed as VTCC 12791 and VTCC 12792) isolated from a pair of mother's breast milk and infant's feces. Both strains completely survived in the simulated gastric juice, highly tolerated the simulated intestinal juice (81-84%), strongly adhered to the HT-29 cell (23.5% for VTCC 12791 strain and 5.5% for VTCC 12792 strain), and had antagonistic activity against food-borne pathogens of Aeromonas dhakensis, Vibrio vulnificus, and Listeria monocytogenes, which demonstrated better beneficial properties than those of the commercial reference Lacticaseibacillus casei Shirota (LcS) strain. Add... Read More

Source

This study aims to explore the preventive effects and underlying mechanisms of Lactobacillus fermentum CKCC1858 (CKCC1), L. fermentum CKCC1369 (CKCC2), Lactobacillus plantarum CKCC1312 (CKCC3), and Lactobacillus gasseri CKCC1913 (CKCC4) on high-fat diet combined with streptozotocin (HFD/STZ)-stimulated type 2 diabetes (T2D) in mice. Generally, the results indicated that most of the four probiotics reduced weight loss and liver and pancreas damage, significantly (p < 0.05) improved glucose metabolism by regulating glucagon-like peptide-1 (GLP-1), fasting glucose and insulin levels, and increasing expression of glucose transporters. Probiotics improved hyperlipemia, inflammation, and oxidative stress by reducing the secretion of blood lipids and proinflammatory cytokines, increasing antioxidant enzymes. Metagenomic results revealed that probiotics restored gut microbiota via enhancing (reducing) the relative abundance of beneficial bacteria (harmful bacteria) and altered specific metabolic pathways in T2D mice. CKCC1, CKCC3, and CKCC4 showed excellent effects compared to CKCC2. These r... Read More

Source

A probiotic bacterial strain, Lactiplantibacillus plantarum IMC 510, isolated from human origin, for use in preventing and treating overweight and obesity. The strain, deposited at DSMZ under DSM 32548, exhibits probiotic properties and is effective in reducing body weight, BMI, waist circumference, and fat mass in overweight and obese individuals.

Source

Preventing and treating metabolic diseases like obesity using a combination of a Lactobacillus fermentum strain and a metabolic regulator. The Lactobacillus strain improves efficacy and reduces side effects of metabolic regulators like GLP-1 analogues. The combination provides better outcomes for obesity treatment compared to using just the metabolic regulator alone.

Source

The status of an impaired gut microbial community, known as dysbiosis, is associated with metabolic diseases such as obesity and insulin resistance. The use of probiotics has been considered an effective approach for the treatment and prevention of obesity and related gut microbial dysbiosis. The anti-obesity effect of Lacticaseibacillus paracasei AO356 was recently reported. However, the effect of L. paracasei AO356 on the gut microbiota has not yet been identified. This study aimed to elucidate the effect of L. paracasei AO356 on gut microbiota and ensure its safety for use as a probiotic.Oral administration of L. paracasei AO356 (107 colony-forming units [CFU]/mg per day, 5 days a week, for 10 weeks) to mice fed a high-fat diet significantly suppressed weight gain and fat mass. We investigated the composition of gut microbiota and explored its association with obesity-related markers.Oral administration of L. paracasei AO356 significantly changed the gut microbiota and modified the relative abundance of Lactobacillus, Bacteroides, and Oscillospira. Bacteroides and Oscillospira wer... Read More

Source

Obesity is a chronic disease that corresponds to excess accumulated fat, has a multifactorial etiology, and is a risk factor for other chronic pathologies. Changes in the diversity and composition of the gut microbiota are increasingly associated with various disease states, including obesity and behavioral disorders. Evidence shows that in obese individuals there are more bacteria of the phylum Firmicutes, than in a person with eutrophic weight, there is more imbalance of the microbiota influenced by the increase in the energetic extraction of the components of the diet, lipogenesis, and intestinal permeability. Thus, studies have shown therapeutic action through intestinal modulation with functional foods, using probiotics, prebiotics and symbiotics, since it is necessary to reduce the public costs assigned to obesity. This work aims to describe the action of probiotics, prebiotics and symbiotics along with a balanced diet for obese adults. This is a systematic review of the literature conducted with publication in the period from 2011 to 2021, which used as database the Medical Li... Read More

Source